Skip to main content

Table 4 Summary of VEGF Trials

From: Therapy for metastatic melanoma: the past, present, and future

Trial Patients RR%
(CR/PR)
PFS
(months)
OS
(months)
Number
(patients)
Summary
Single Arm Phase 2
Perez et al. [61]
Carboplatin plus paclitaxel and bevacizumab in unresectable metastatic melanoma 17 6 12 53 Carboplatin plus paclitaxel and bevacizumab was well tolerated and clinically beneficial
Randomized Phase 2
Kim et al. [62]
Carboplatin plus paclitaxel and bevacizumab versus
Carboplatin plus paclitaxel in untreated metastatic melanoma
25.5
versus
16.4
5.6
versus
4.2
12.3
versus
8.6
214 Carboplatin plus paclitaxel and bevacizumab demonstrated statistically significant improvement in OS
Single Arm
Phase 2
Kottschade et al. [63]
Carboplatin plus nab-paclitaxel in chemotherapy naïve(CN) and previously treated (PT) metastatic melanoma 25.6 (CN)
8.8 (PT)
4.5 (CN)
4.1 (PT)
11.1 (CN)
10.1 (PT)
41 (CN)
35 (PT)
Carboplatin plus nab-paclitaxel has clinical activity in chemotherapy naïve patients
Single Arm Phase 2
Fruehauf et al. [64]
Axitiniba in metastatic melanoma after maximum on one prior therapy 18.8% 3.9 6.6 32 Axitinib demonstrated clinical activity in metastatic melanoma.
  1. aAxitinib is an oral second-generation inhibitor of VEGF receptors 1, 2, and 3. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response RR, response rate.